Biology Atlas

Map / Drugs

drug · intermediate · complete

1999 adenoviral gene transfer trial for OTC deficiency

A 1999 safety trial of an adenoviral vector carrying the OTC gene, ended by the death of an 18-year-old participant from a systemic inflammatory response.

Also called: adenovirus OTC trial, OTC deficiency gene therapy trial

This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.

What happened

In a dose-escalation safety study of an adenoviral vector carrying the OTC gene, an 18-year-old participant with partial OTC deficiency died 98 hours after the top dose was infused into the liver artery. The cause was a systemic inflammatory response to the vector. The trial was stopped and gene therapy changed how it tests immune risk. 1

Reported, not yet replicated

Design and the earlier subjects more

The study gave adults with partial OTC deficiency a vector in six cohorts of 3 or 4 participants, on half-log steps from 2 x 10^9 to 6 x 10^11 particles/kg. Earlier subjects had flu-like illness, fever and changes in liver enzymes and platelets. Transgene expression was seen in hepatocytes of 7 of 17 and there was no significant metabolic correction (abstract of the 2002 report). 2

Reported, not yet replicated

The decisive event more

The 18th subject, 18 years old, received the top dose of 6 x 10^11 particles/kg into the right hepatic artery. At about 18 hours there was altered mental status and jaundice, which the first 17 subjects had not shown. The course then went to systemic inflammatory response syndrome, biochemically detectable disseminated intravascular coagulation, and multiple organ failure, with death at 98 hours. Serum IL-6 and IL-10 were high and TNF-alpha normal immediately after infusion; post-mortem found vector DNA in most tissues. 1

Reported, not yet replicated

Why it failed more

The authors give four reasons in their abstract: animal studies were limited in predicting the human response; replication-defective adenovirus vectors have a steep toxicity curve; there is large subject-to-subject variation in the host response to systemically given vectors; and the immune response to these vectors needed more study. That is, the dose sat near an inflammatory cliff of the capsid itself, not of the gene. A later paper argues prior immunity to natural adenovirus amplified the reaction; this atlas could not open it, so that is not carried here. 1

Reported, not yet replicated

Process and regulatory aftermath (allegations) deep

FDA's 2002 hearing notice alleges that stopping rules were ignored after two Grade III liver-enzyme events, that a subject with a baseline neutralising antibody titre of 1280 (excluded by protocol) and another with raised ammonia were enrolled, that protocol changes were not reported, and that the consent form omitted the risk of disseminated intravascular coagulation; it also states that a monkey given a related vector had DIC in October 1998. These are allegations, not findings, and the notice says FDA had made no final decision. Whether the allegations were contested is not verified here. 3

Reported, not yet replicated

Contrast with Zolgensma deep

Both products put a gene in a viral shell. The units differ (particles for adenovirus, vector genomes for AAV), so the doses cannot be compared by size of number. AAV9 is less inflammatory per particle, and the Zolgensma label adds an antibody screen, steroid cover and liver monitoring; its boxed liver warning shows the dose-toxicity wall remains. Whether the difference between the two cases is the vector, the dose, the route or process discipline cannot be isolated from these records: it is an inference from the cited documents. 14

Our inference

Modality

Gene therapy

Targets

Pathways

Indications

Identifiers

Vector

human adenovirus type 5, deleted in E1 and E4, carrying human OTC cDNA

Mechanism

A replication-defective human adenovirus type 5 vector, deleted in E1 and E4, carried human OTC cDNA. The aim was to give liver cells a working copy of the missing urea-cycle enzyme. The vector was a transient delivery vehicle for the gene, but the adenovirus capsid itself provokes a strong innate immune response. 1

Reported, not yet replicated

Delivery route

Must survive

The vector was infused into the right hepatic artery, directly toward the liver, at doses up to 6 x 10^11 particles/kg. It had to avoid pre-existing immunity and inflammatory reaction; the abstract reports that the dose given to the fatal case produced a systemic reaction. 1

Reported, not yet replicated

Side effects

Earlier participants

Flu-like illness, fever and changes in transaminases and platelets were reported in the earlier subjects, with transgene expression seen in hepatocytes of 7 of 17 and no significant metabolic correction. 2

Reported, not yet replicated

Fatal systemic inflammatory response

In the 18th subject, an 18-year-old male at the top dose, altered mental status and jaundice appeared at about 18 hours, followed by systemic inflammatory response syndrome, disseminated intravascular coagulation and multi-organ failure; death at 98 hours. IL-6 and IL-10 were high and TNF-alpha normal; vector DNA was detectable in most tissues. These signs had not been seen in the first 17 subjects. 1

Reported, not yet replicated

Verdict

Outcome

failed

Why

The trial ended with the participant's death. The authors name the lessons: animal studies did not predict the human response, replication-defective adenovirus has a steep toxicity curve, host responses to systemically given vectors vary a great deal between people, and the immune response needs study. At lower doses the vector had also hardly corrected the metabolism. 12

Reported, not yet replicated

Failure mode

Systemic inflammatory response syndrome with disseminated intravascular coagulation and multi-organ failure, beginning about 18 hours after the vector reached the liver and ending in death at 98 hours, at the highest dose of a dose-escalation. FDA's 2002 notice alleges, and these are allegations rather than findings, that stopping rules were not followed after liver-enzyme events, that a participant with a high baseline neutralising antibody titre and another with raised ammonia were enrolled, that protocol changes were not reported and that the consent form lacked the clotting risk; the notice states FDA had made no final decision. The trial was terminated in September 1999 according to our own earlier report's reading of the notice. 13

Reported, not yet replicated

Teach this

In one sentence

A gene therapy is also a dose of virus, and in 1999 a dose of adenovirus into the liver set off a lethal inflammatory reaction that animal studies had not predicted. 1

Reported, not yet replicated

The five-minute version

Adults with partial OTC deficiency were given an adenovirus carrying the missing gene, at rising doses. Earlier participants had fever and liver changes but no major benefit. At the top dose, the 18th participant became confused and jaundiced within about 18 hours and died at 98 hours of systemic inflammation, clotting failure and organ failure. The authors concluded that the toxicity curve was steep and that the immune response to the vector needed study. Regulators later alleged that protocol safeguards had not been followed. 123

Reported, not yet replicated

What a listener will ask

Was the gene the problem?

The authors point to the immune response to the vector, not to the OTC gene.

Why did animals not predict it?

The authors state that animal studies were limited in predicting human responses to this vector.

Was misconduct proven?

No. The notice lists allegations, and states that no final decision had been made.

The common wrong idea

The gene being delivered is what makes gene therapy dangerous.

The shell carrying it is a biological particle that the immune system reacts to, and the reaction can be the lethal part.

The one citation to hand over: 1

Still open here

Not yet written: Assays used, Off targets.

Linked from

Sources

  1. Raper SE, Chirmule N, Lee FS, et al.. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Molecular Genetics and Metabolism (2003). paper; opened 2026-11-17 all records citing this
  2. Raper SE et al.. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Human Gene Therapy (2002). paper; opened 2026-11-17 all records citing this
  3. US Food and Drug Administration. FDA notice (2002) concerning the 1999 OTC-deficiency adenoviral gene transfer trial: allegations, not findings. FDA electronic reading room (2002). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
  4. US Food and Drug Administration. ZOLGENSMA (onasemnogene abeparvovec-xioi) prescribing information, revision 6/2026. FDA (2026). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (6)

This record has been changed 6 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.

Year
1999
Regulatory status
failed-in-trials
Status
complete
Last updated
2026-11-19
Record
content/drugs/ad-otc-gene-transfer-trial-1999.json